AU2021105727A4 - A method of preparation of Silk Fibroins coated with Hybrid chitosan-ZnO nanoparticles for wound dressing. - Google Patents
A method of preparation of Silk Fibroins coated with Hybrid chitosan-ZnO nanoparticles for wound dressing. Download PDFInfo
- Publication number
- AU2021105727A4 AU2021105727A4 AU2021105727A AU2021105727A AU2021105727A4 AU 2021105727 A4 AU2021105727 A4 AU 2021105727A4 AU 2021105727 A AU2021105727 A AU 2021105727A AU 2021105727 A AU2021105727 A AU 2021105727A AU 2021105727 A4 AU2021105727 A4 AU 2021105727A4
- Authority
- AU
- Australia
- Prior art keywords
- patil
- zno nanoparticles
- ravsaheb
- shivaji
- sujit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 73
- 238000000034 method Methods 0.000 title claims abstract description 39
- 108010022355 Fibroins Proteins 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 37
- 239000002131 composite material Substances 0.000 claims abstract description 30
- 239000000463 material Substances 0.000 claims abstract description 25
- 230000035876 healing Effects 0.000 claims abstract description 12
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 19
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 19
- 229920001661 Chitosan Polymers 0.000 claims description 11
- 239000012620 biological material Substances 0.000 claims description 10
- 238000000576 coating method Methods 0.000 claims description 10
- 229920001817 Agar Polymers 0.000 claims description 5
- 239000008272 agar Substances 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 238000010586 diagram Methods 0.000 claims description 4
- 238000009792 diffusion process Methods 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 238000013272 agar well diffusion method Methods 0.000 claims description 3
- 230000002776 aggregation Effects 0.000 claims description 3
- 238000004220 aggregation Methods 0.000 claims description 3
- 238000005266 casting Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000002604 ultrasonography Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 2
- 238000004807 desolvation Methods 0.000 claims 2
- 241000894006 Bacteria Species 0.000 abstract description 7
- 239000002245 particle Substances 0.000 abstract description 6
- 230000005012 migration Effects 0.000 abstract description 5
- 238000013508 migration Methods 0.000 abstract description 5
- 231100000252 nontoxic Toxicity 0.000 abstract description 4
- 230000003000 nontoxic effect Effects 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 abstract description 3
- 230000018044 dehydration Effects 0.000 abstract description 3
- 238000006297 dehydration reaction Methods 0.000 abstract description 3
- 150000002500 ions Chemical class 0.000 abstract description 3
- 210000002510 keratinocyte Anatomy 0.000 abstract description 3
- 230000000845 anti-microbial effect Effects 0.000 abstract 1
- 239000002086 nanomaterial Substances 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 description 62
- 208000027418 Wounds and injury Diseases 0.000 description 61
- 239000010408 film Substances 0.000 description 26
- 239000000243 solution Substances 0.000 description 17
- 208000015181 infectious disease Diseases 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000006260 foam Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 230000001070 adhesive effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- 239000000835 fiber Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 229910044991 metal oxide Inorganic materials 0.000 description 4
- 150000004706 metal oxides Chemical class 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000002828 disc diffusion antibiotic sensitivity testing Methods 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003106 tissue adhesive Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 241000255789 Bombyx mori Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 206010048038 Wound infection Diseases 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001027 hydrothermal synthesis Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 231100001083 no cytotoxicity Toxicity 0.000 description 2
- 239000006916 nutrient agar Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000012763 reinforcing filler Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229910052984 zinc sulfide Inorganic materials 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 229910014813 CaC2 Inorganic materials 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000005230 Leg Ulcer Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229920005830 Polyurethane Foam Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108010013296 Sericins Proteins 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000009388 chemical precipitation Methods 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000001523 electrospinning Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001699 photocatalysis Effects 0.000 description 1
- 229920006264 polyurethane film Polymers 0.000 description 1
- 239000011496 polyurethane foam Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 229920006126 semicrystalline polymer Polymers 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003836 solid-state method Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000006557 surface reaction Methods 0.000 description 1
- 239000003356 suture material Substances 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/225—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D105/00—Coating compositions based on polysaccharides or on their derivatives, not provided for in groups C09D101/00 or C09D103/00
- C09D105/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D5/00—Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes
- C09D5/14—Paints containing biocides, e.g. fungicides, insecticides or pesticides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/04—Coatings containing a composite material such as inorganic/organic, i.e. material comprising different phases
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/18—Oxygen-containing compounds, e.g. metal carbonyls
- C08K3/20—Oxides; Hydroxides
- C08K3/22—Oxides; Hydroxides of metals
- C08K2003/2296—Oxides; Hydroxides of metals of zinc
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K2201/00—Specific properties of additives
- C08K2201/011—Nanostructured additives
Abstract
:
A method of preparation of Silk Fibroins coated with Hybrid chitosan-ZnO
nanoparticles for wound dressing.
This invention formulates a new dressing material for wound dressing application with
antimicrobial property using nanomaterials. Here a composite material is synthesized into
the wound dressing materials to provide the best healing action. It is made biocompatible,
and it prevent dehydration, maintain appropriate moist humidity to wound area allowing
gas permeation, prevention against foreign particles and bacteria. It is nontoxic, it has
easy to apply and removing and showing compatible with blood. Here a method and
preparation of ZnO Nanoparticles embedded SF-PVA and hybrid chitosan-ZnO
Nanoparticles coated SF-PVA composite films is used for the preparation of the composite
film that will enhance the antibacterial and mechanical properties of wound dressing
material. The ZnO Nanoparticles Release Zn+ ions, and they can improve keratinocytes
migration towards the wound area and enhance the healing process.
SIGNATURE:
Dr. Priyanka Popat Patil
Dr Abhinandan Ravsaheb Patil
Dr. Shivaji Pawar
Dr. Sujit Kumar Mishra
Description
TITLE A method of preparation of Silk Fibroins coated with Hybrid chitosan ZnO nanoparticles for wound dressing.
[0001] This invention relates to the field of pharmaceuticals and medical sciences more particularly a method of development of antibacterial dressings based on nano biomaterials to reduce the risk of infection in partial and full-thickness wounds. Here ZnO Nanoparticles embedded Silk Fibroin (SF)-Polyvinyl alcohol (PVA) and hybrid chitosan-ZnO Nanoparticles coated SF-PVA composite films are synthesized for preparing silk fibroins based wound dressing. The designed wound dressing prevents dehydration, maintain appropriate moist humidity to the wound area allowing gas permeation, prevention against foreign particles and bacteria. It is nontoxic, it has easy to apply and removing and showing compatibility with blood.
[0002] The healing progress of wound is an intricate method that demands a proper environment to encourage the healing steps. Microbial contamination and its infectious colonies are the main reason of death for at least 10,000 people for every million wound patients. Other factors are included as oxygenation, age and gender, stress, sex hormones in aged individuals, diabetes, medications, obesity, nutrition, alcohol consumption and smoking. These factors are the main factors for the delay in the process of wound healing. Thus, the ideal wound dressing is the major need in wound care management. With the improvement in processing, more than 3,000 products have been developed for the treatment of various types of wounds by treating different forms of healing. Currently, there are different wound dressings depends on interactive and bioactive materials applicable to the healing process.
[0003] These are significantly different dressings comprised of traditional in keeping and developing a humid environment around the area of wound facilitating wound steps. The modem types of wound dressings are developed by employing synthetic polymers. These are primarily categorized as foam, film, gel, and hydrocolloids. The modern wound dressings offer preventions of infections to the wound environment.
[0004] Film dressings are suitable for primary and secondary wound dressings adhesive to allow adherence to the skin. These films are permeable to water and air. These materials are flexible and elastic. Film dressings are suggested for epithelializing wound, lower exudates wounds. Foam dressing consists of porous polyurethane foam or film forms. The outer layer of dressings has hydrophobic. This layer is impermeable to liquid. The inner layer of foam dressing has permeable to water and 02, C02, and water vapor exchange due to its porosity. It is protective, provide thermal insulation, highly absorbent, and maintain a moist environment. These types of dressings are used to prevent infections. Additionally, it is nonadherent, easy to apply and remove processes. The absorbency of foam dressings can be controlled by foam properties. It is available in different sizes or shapes. Foam dressings are recommended for granulating wounds and lower leg ulcers.
[0005] Gauze is the most available wound dressing in use today were made from woven or nonwoven gauze. It is highly absorbent and comparatively non-barrier due to it may promote dryness in wounds. In gauze dressings, sterile gauze pads are selected for absorbing a large volume of wound exudates in an open wound with the use of fibers. Gauze dressings require constant changing to safe from the exhaustion of healthy tissues. These types of dressings are reasonable cost and easy for manufacturing. Gauze becomes moistened due to intense wound effluent. Moreover, it becomes more adhesive to the wound area creating it painful when removing process.
[0006] To resolve the above-stated problem here a wound dressing is designed by synthesizing ZnO Nanoparticles embedded SF-PVA and hybrid chitosan ZnO Nanoparticles coated SF-PVA composite films for enhancing the antibacterial and mechanical properties of the dressing material. The ZnO nanoparticles are synthesizing reinforcing fillers for a polymer matrix due to their excellent antibacterial activity. Moreover, they do not show any adverse effects on normal cells when used in appropriate concentrations. In addition, ZnO Nanoparticles release Zn+ ions, and they can improve keratinocytes migration towards the wound area and enhance the healing process.
[0007] Fast wound closure is the first aim in the care of acute or chronic wounds, where healing is impaired because of infections. The infectious wound is the large complications in the area of wound care management. These infections can cause a delay in the healing process. Wound infection is caused by indigenous microflora or environments, which grow immediately in the wounded area. This problem can be prevented by protecting the wound with proper antibacterial dressing materials. The control of infections within the area of the wound is due to the antibacterial agents. These antibacterial agents play an essential role to prevent the wound from infections.
[0008] It has already been proposed where dressing materials made of natural biopolymers such as collagen, elastin are available among these, collagen dressings are mostly used to support cell activities, differentiation, and migrations. Collagen has synthesized by animal sources; it may stimulate immunological responses and transfer pathogens to the host tissue. The synthesis of collagen is not easy and it's challenging from a cost perspective. The mechanical strength of collagen is very poor. These disadvantages of collagen restrict its applications for wound dressings. Elastin is natural biopolymers. Due to its elasticity property, it is used in commercial dressings. The highly cross-linked structure of elastin hinders its processability and decreases its solubility. Therefore, it is limited supplies as it originates from biotechnology-derived sources.
[0009] The principal objective of the invention is to enhance the antibacterial activity and the mechanical property of composite films by surface modification of chitosan-ZnO Nanoparticles to form C@ZnO hybrid system that enhances the properties of biocompatibility, biodegradability, non-toxicity, moisture retentive ability, antibacterial activity in the preparation of wound dressing applications.
[0010] Another objective of the invention is the use of Sonochemical coating technique to prevent the aggregation of Nanoparticles due to the application of high-intensity ultrasound and the acquired coatings are uniformly deposited on the surface of substrates.
[0011] The further objective of the invention to synthesize the pure materials of SF, PVA and ZnO Nanoparticles. SF is synthesized by chemical desolation method, while the ZnO Nanoparticles are synthesized by the reflux method.
[0012] The further objective of the invention is to synthesize hybrid chitosan-ZnO Nanoparticles by mixing the chitosan and ZnO Nanoparticles by desolation method.
[0013] The further objective of the invention is to synthesize composite films of SF-PVA, ZnO Nanoparticles embedded SF-PVA by casting method at room temperature.
[0014] There are multiple factors that affect wound healing process. These are categorized into two factors local or intrinsic and systematic. Local factors are insufficient blood supply, foreign bodies, infection on the wound site, topical steroids and antiseptic. Systematic factors are the overall health or disease, aging and general health of the body. Any wound fails to heal within a few weeks should be expected by a healthcare professional. It might be a chronic wound. This is due to the bacterial infection or might show an underlying disease such as diabetes, fibrosis, jaundice and others. The major risk of wound infection is increased by the concentration of pathogens and the presence of vascular disease, edema, malnutrition, diabetes, and corticosteroids. If the wound is deeper or over a large area and the tissue is necrotic then the patient is more susceptible to infection. The main signs of the soft tissue infections are pus formation, increased swelling of the wound site, increased erythema, pain, odor and fever for patients. This problem can be overcome by protecting the wound from proper antibacterial wound dressing materials. Based on these, different types of dressings are available in the market. Most of these dressing materials are lacking one or the other reasons such as low level of mechanical properties, insufficient blood clotting ability, lower swelling ability, and inadequate antibacterial activity. Hence, there is an immense need to formulate new dressing materials for wound dressing application. Here in this invention biomaterials based composite materials is synthesized into the wound dressing materials to provide the best healing action. It is made biocompatible, and it prevent dehydration, maintain appropriate moist humidity to wound area allowing gas permeation, prevention against foreign particles and bacteria. It is nontoxic, it has easy to apply and removing and showing compatible with blood. Here a method and preparation of ZnO Nanoparticles embedded SF PVA and hybrid chitosan-ZnO Nanoparticles coated SF-PVA composite films is described for enhancing the antibacterial and mechanical properties of wound dressing material.
[0015] While the present invention is described herein by way of example, using various embodiments and illustrative drawings, those skilled in the art will recognize that the invention is neither intended to be limited to the embodiment of drawing or drawings described nor designed to represent the scale of the various components. Further, some components that may form a part of the invention may not be illustrated with specific figures, for ease of illustration, and such omissions do not limit the embodiment outlined in any way. The drawings and detailed description of it are not intended to restrict the invention to the form disclosed, but on the contrary, the invention covers all modifications, equivalents, and alternatives falling within the spirit and scope of the present invention as defined by the appended claims. The headings are used for organizational purposes only and are not meant to limit the scope of the description or the claims. As used throughout this specification, the worn "may" be used in a permissive sense (i.e., meaning having the potential to), rather than the mandatory sense (i.e., meaning, must).
[0016] Further, the words "an" or "a" mean "at least one" and the word "plurality" means one or more unless otherwise mentioned. Furthermore, the terminology and phraseology used herein is solely used for descriptive purposes and should not be construed as limiting in scope. Language such as "including," "comprising," "having," "containing," or "involving," and variations thereof, is intended to be broad and encompass the subject matter listed thereafter, equivalents and any additional subject matter not recited, and is not supposed to exclude any other additives, components, integers or steps. Likewise, the term "comprising" is considered synonymous with the terms "including" or "containing" for applicable legal purposes. Any discussion of documents acts, materials, devices, articles and the like are included in the specification solely to provide a context for the present invention.
[0017] In this disclosure, whenever an element or a group of elements is preceded with the transitional phrase "comprising", it is also understood that it contemplates the same element or group of elements with transitional phrases "consisting essentially of, "consisting", "selected from the group comprising", "including", or "is" preceding the recitation of the element or group of elements and vice versa.
[0018] Before explaining at least one embodiment of the invention in detail, it is to be understood that the present invention is not limited in its application to the details outlined in the following description or exemplified by the examples. The invention is capable of other embodiments or of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein is for description and should not be regarded as limiting.
[0019] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Besides, the descriptions, materials, methods, and examples are illustrative only and not intended to be limiting. Methods and materials similar or equivalent to those described herein are used in the practice or testing of the present invention.
[0020] In the present invention hybrid chitosan-ZnO nanoparticles (C@ZnO Nanoparticles) are synthesized and coated on Silk fibroin-polyvinyl alcohol (SF-PVA) composite film by a sonochemical coating process for creating a composite file that can be used for an antibacterial wound dressing material. The coated composite films show the excellent antibacterial activity against Gram-positive and Gram-negative bacteria. It provides add-on benefits apart from preventing microbial growth such as inhibition of bleeding, maintaining a moist environment at the wound interfaces, provide flexibility, non-cytotoxicity, and should be allowing water and vapor permeability. All this will lead to faster wound healing process.
[0021] Silk Fibroin (SF) is one of the most abundant biomaterials in nature. SF is a biocompatible and eco-friendly material which is isolated from B. mori silk cocoons. Due to its wide availability, biodegradability, water absorption capacity and biocompatibility, SF has been used in wound dressing applications in combination with polymers. The applications of SF as biomaterials in wound dressings have been growing in recent years. SF fibers are used in textile industries from ancient times due to its softness, lustrous appearance, ease of dyeing and moisture absorption capacity. Apart from this, SF have desirable properties of high strength, biocompatibility, biodegradability, lower adherence of microorganisms, and easy to handle. Therefore, it is mostly applied as suture materials in the medical field. SF can be easily fabricated into nanofibrous mats, scaffolds, sponges, hydrogels, microparticles and nanoparticles (Nanoparticles), and composite films for biomedical applications namely tissue engineering, drug delivery, cancer therapy, skin wound healing and wound dressing applications. The advantages of SF in wound dressing applications have shown porosity, high strength, flexibility, oxygen permeability, cell adhesion, migration, proliferation capacity and non cytotoxicity.
[0022] Polyvinyl alcohol (PVA) is one of the polymers that improves the mechanical properties and to promote cell growth, but without incorporation of an antibacterial agent, the SF and PVA are incapable to produce the antibacterial effects. PVA is a synthetic polymer, soluble in water, nontoxic and semicrystalline polymer have been applied in several advanced biomedical applications e.g., wound dressings, drug delivery system, artificial organs and contact lenses. It has possessed various useful properties, such as biocompatibility, gas barrier properties, high strength, flexibility, and excellent membrane-forming properties together with high thermal stability making it an effective polymer to be used in wound dressing applications [66]. Blends of SF and PVA have been extensively used in dressing application since these blends can be prepared with good mechanical, biocompatible and biodegradable properties. Additionally, the degree of crystallinity, mechanical property, and the thermal property was improved with the incorporation of SF fibers as compared to pure PVA
[67]. The blended films of SF, PVA and starch were developed by a solution casting method and examined for their mechanical property, antibacterial efficacy and biodegradability.
[0023] The blended films have improved mechanical property, good bacteria killing ability against S. aureus and E. coli bacteria and showed biodegradability by addition of SF particles. Electrospinning has developed a new and suitable technology for the formation of tissue engineering matrices and PVA is selected as the polymer additive to produce electro spun nanofibrous matrix due to its good fiber forming properties. Both the composites were used for wound dressing applications. However, the results of the antibacterial study showed that the blended films inhibited only those organisms that were in direct contact with the active sites of the blended films. Improvement in antibacterial activity of the prepared dressings urgently required, when they are used for infected wound care. SF and PVA do not show any antibacterial activity at neutral pH, which limits their use in infected wound care.
[0024] This problem is overcome by the addition of inorganic materials such as metal oxide Nanoparticles. Among different metal oxides, ZnO Nanoparticles are important and are considered as reinforcing fillers for a polymer matrix due to their excellent antibacterial activity. Moreover, they do not show any adverse effects on normal cells when used in appropriate concentrations. In addition, ZnO Nanoparticles release Zn+ ions, and they can improve keratinocytes migration towards the wound area and enhance the healing process
[0025] ZnO Nanoparticles have good tissue adhesive property, high ability and antibacterial activity. In addition, this system gives the flexibility to enhance the biocompatibility by modifying the surface with biocompatible polymers. Among the metal oxide Nanoparticles, ZnO Nanoparticles are of special interest. ZnO Nanoparticles belongs to inorganic, metal oxide Nanoparticles are increasingly important as one of the newest class of materials. Due to its antibacterial, biocompatible, and tissue adhesive properties, ZnO Nanoparticles are capable and best filler in wound dressing application. ZnO Nanoparticles have gained much of interest as future materials due to their interesting effects namely large surface-to-volume ratio, high surface reaction activity, high catalytic effects, and strong adsorption capacity, which make ZnO Nanoparticles are suitable candidates for a broad range of applications. ZnO Nanoparticles are excellent candidate with a direct band gap (3.37 eV) and it is a semiconducting material. ZnO Nanoparticles are widely used in near UV-emission, piezoelectric, nano sensors, energy storage, transparent conductor, cosmetics etc. applications. ZnO Nanoparticles crystals form hexagonal wurtzite and cubic zinc blend structure.
[0026] The most general and stable structure at atmospheric condition of ZnO Nanoparticles is hexagonal wurtzite structure. Another structure, zinc blend can be stabilized by formation of ZnO on substrates with a cubic lattice form. The centers of zinc and oxide are tetrahedral in both type of structure. ZnO Nanoparticles have been formulated by interested high temperature solid-state method. In large scale, ZnO Nanoparticles can be synthesized by low coast simple solution based chemical precipitation, sol-gel type and hydrothermal reaction method. The hydrothermal process is important for controlling the particle size of ZnO Nanoparticles. These types of Nanoparticles have described wide interest because of its high stability, less cytotoxicity good photocatalytic activity and from use in electronics and solar cells to biomedical application. The production of the hydrogen peroxide at its surface results in outstanding antibacterial activity therefore, the utilization of these ZnO Nanoparticles in various hydrogen-based dressing materials. ZnO Nanoparticles shows good biocompatibility and tissue adhesive properties. Based on these interesting properties ZnO Nanoparticles is used in wound healing application.
[0001] So, in this embodiment synthesis of hybrid chitosan-ZnO Nanoparticles (C@ZnO Nanoparticles) is performed on SF-PVA composite film. the antibacterial activity and the mechanical property of composite films by surface modification of chitosan-ZnO Nanoparticles to form C@ZnO hybrid system. Sonochemical coating technique prevents the aggregation of Nanoparticles due to the application of high-intensity ultrasound and the acquired coatings are uniformly deposited on the surface of substrates. For the synthesis of hybrid Chitosan-ZnO Nanoparticles, Hybrid C@ZnO Nanoparticles are prepared by blending of chitosan and ZnO Nanoparticles. Chitosan 2% solution is prepared using a 4% acetic acid solution and stirred for 4 hours. Undissolved chitosan particles removed by using muscling cloth. The process is repeated 2 to 3 times to prepared homogenous chitosan solution. Deposition of ZnO Nanoparticles is achieved by dispersing the ZnO Nanoparticles in prepared chitosan solution at a concentration of 1:1 ratio and stirred continuously for 2 hours, followed by adjusting a neutral pH. The prepared solution is dried in an oven at 50 °C to obtain hybrid C@ZnO Nanoparticles.
[0002] For the preparation of SF-PVA composite film, stock solutions of SF and PVA is blended at a concentration of 7 wt.%. SF aqueous stock solutions were prepared as described above. Cocoons of Bombyx mori degummed by boiling an aqueous solution of 0.02 M Na2CO3 for 30 minutes and then rinsed thoroughly with distilled water to remove sericin. After air-drying the extracted SF is dissolved in CaC2: H20: ethanol solution (mole-ratio 1:8:2) at 70 °C for 4 h yielding 20% solution. The solution is dialyzed against distilled water using Slide-a-Lyzer dialysis membrane, for 3 days to remove the salt. The solution is centrifuged two times at 10,000 rpm for 20 min to remove salt aggregates and debris from original cocoons. The final solution of SF aqueous solution is adjusted to approximately 7% (w/v), that is determined by weighing the remaining solid weight after drying at 60 °C by rotary evaporation. 7 g of PVA stirred at 80 °C for 2 h. As prepared SF solution was mixed with PVA solution at a concentration of 1:2 ratios and stirred for 1 hour. The composite solution is transferred to a petri dish and dried at room temperature for 48 hours.
[0003] Surface coating of C@ZnO Nanoparticles on SF-PVA composite film is carried out by a sonochemical method using an ultrasonic transducer (Ti horn, 20 KHz, 600W, Sonics and Materials VCX 600) [36]. During the process of coating, the concentrations of C@ZnO Nanoparticles are varied, which is 0.2 wt.%, 0.5 wt.%, and 1 wt.%. The composite films are held immersed in a solution of C@ZnO Nanoparticles in the water, followed by the solution is irradiated for 15 min with a high-intensity ultrasonic horn in different flasks. After sonication, the coated composite films are dried at room temperature.
[0004] The prepared composite films were tested for its antibacterial properties when used for wound dressing. Antibacterial activity is involving two basic activities such as bactericidal activity and bacteriostatic activity. The bactericidal activity is antibacterial agents or other substances that kill the bacteria, the use of whereas the bacteriostatic activity is defined as the use of antibacterial agents or other substances that kill the bacterial growth. Antibacterial materials are used to fight against infections. Hence, there are different methods employed for investigation of antibacterial activity of different antibacterial agents or other substances. These methods include Agar disc diffusion method, Agar well diffusion method and Shake flask method.
[0005] The disc diffusion method is easy, important and most widely method for antibacterial activity study. In the disc diffusion method, the first target organism suspension spread on the surface of nutrient agar medium and then the paper disc of antibacterial agents or tested samples deposited on the surface of sterile medium plate. Further, the tested sample discs diffused in medium by plates kept in refrigerator for 10 min. After the plates are incubated at 37 0 C for 24 h, the zone of inhibition (ZOI) around each disc are determined by using the scale in millimeter.
[0006] In agar well diffusion process, the wells (6 mm in diameter) are prepared by applying sterile cork borer and the target organism suspension is spread over the nutrient agar medium. The tested liquid sample of volume 70-80 pl is aseptically dispensed into each well and plates are kept at 4 C for 10 min to facilitate the diffusion of sample in the agar medium. After plates are incubated at 370 C for 24 h and the ZOI is measured around each well.
[0007] In the shake flask method, the nutrient broth is prepared and dispensed in flask aseptically. The tested samples as well as microbial suspension are aseptically dispensed into the flask and the flasks are kept in shaking incubator at 180 rpm for 24 h at 37 0 C. The growth of organisms is observed in the form of turbidity. The growth of organism is determined by using optical density.
[0008] The tests showed that that the antibacterial activity of chitosan is due to its positively charged amino groups, which can form electrostatic interactions with an anionic group of the microbial cell surface, inducing changes in permeability, metabolic disturbances and finally death. Additionally, the antibacterial activity can be enhanced due to interactions with is zinc ion release mechanism. When ZnO Nanoparticles (E.g., = 3.37 eV) were under light irradiation, the resulted in electron-hole pairs. This hole (h+) reacted with OH\\on the surface of ZnO Nanoparticles, generating hydroxyl radicals (OH•), superoxide anion (02\\) and perhydroxyl radicals (H02•). These free radicals damaged the cells of bacteria as a result of decomposition and complete destruction of microorganisms.
[0009] While there has been illustrated and described embodiments of the present invention, those of ordinary skill in the art, to be understood that various changes may be made to these embodiments without departing from the principles and spirit of the present invention, modifications, substitutions and modifications, the scope of the invention being indicated by the appended claims and their equivalents.
[0010] The accompanying drawings, which are incorporated in and constitute a part of this disclosure, illustrate an exemplary embodiment and, together with the description, explain the disclosed embodiment. In the figures, the left and rightmost digit(s) of a reference number identifies the figure in which the reference number first appears. The same numbers are used throughout the figures to reference features and components. Some embodiments of the system and methods of an embodiment of the present subject matter are now described, by way of example only, and concerning the accompanying figures, in which:
[0011] Figure 1 illustrates the Structures of ZnO Nanoparticles
[0012] Figure 2 shows the Schematic diagram of Nanoparticles embedded composite film.
[0013] Figure 3 shows the Schematic diagram of Nanoparticles surface coated composite film.
[0014] Figure 4 shows the Schematic representation of the agar disc diffusion antibacterial activity
[0015] Figure 5 illustrates the Schematic representation of the agar well diffusion method for antibacterial activity.
[0016] Figure 6 shows the Schematic representation of shake flask method for antibacterial activity.
Claims (5)
1. A method of preparation method of biomaterials based composite materials is synthesized into the wound dressing materials to provide the best healing action composition of; Silk Fibron polyvinyl alcohol ZnO Nanoparticles
2. The biomaterial preparation method as claimed in claim - 1, consist of hybrid chitosan ZnO nanoparticles (C@ZnO Nanoparticles) synthesized and coated on Silk fibroin polyvinyl alcohol (SF-PVA) composite film by a sonochemical coating process for creating a composite file.
3. The biomaterial preparation method as claimed in claim - 1, uses Sonochemical coating technique to prevent the aggregation of Nanoparticles due to the application of high intensity ultrasound and the acquired coatings are uniformly deposited on the surface of substrates. The biomaterial preparation as claimed in claim - 1, has the Silk fibron (SF) synthesized by chemical desolvation method, while the ZnO Nanoparticles synthesized by the reflux method.
4. The biomaterial preparation method as claimed in claim - 1, synthesizes the hybrid chitosan-ZnO Nanoparticles by mixing the chitosan and ZnO Nanoparticles by desolvation method.
5. The biomaterial preparation method as claimed in claim - 1, synthesizes composite films of SF-PVA, ZnO Nanoparticles embedded SF-PVA by casting method at room temperature.
Signatory:
Dr. Priyanka Popat Patil
Dr Abhinandan Ravsaheb Patil
Dr. Shivaji Pawar
Dr. Sujit Kumar Mishra
Sheet 1 of 6
APPLICANT 18 Aug 2021
Dr. Priyanka Popat Patil Dr Abhinandan Ravsaheb Patil Dr. Shivaji Pawar Dr. Sujit Kumar Mishra 2021105727
Figure 1 Structures of ZnO NPs
Signatory:
Dr. Priyanka Popat Patil
Dr Abhinandan Ravsaheb Patil
Dr. Shivaji Pawar
Dr. Sujit Kumar Mishra
Sheet 2 of 6
APPLICANT 18 Aug 2021
Dr. Priyanka Popat Patil Dr Abhinandan Ravsaheb Patil Dr. Shivaji Pawar Dr. Sujit Kumar Mishra 2021105727
Figure 2 Schematic diagram of NPs embedded composite film.
Signatory:
Dr. Priyanka Popat Patil
Dr Abhinandan Ravsaheb Patil
Dr. Shivaji Pawar
Dr. Sujit Kumar Mishra
Sheet 3 of 6
APPLICANT 18 Aug 2021
Dr. Priyanka Popat Patil Dr Abhinandan Ravsaheb Patil Dr. Shivaji Pawar Dr. Sujit Kumar Mishra 2021105727
Figure 3 Schematic diagram of NPs surface coated composite film.
Signatory:
Dr. Priyanka Popat Patil
Dr Abhinandan Ravsaheb Patil
Dr. Shivaji Pawar
Dr. Sujit Kumar Mishra
Sheet 4 of 6
APPLICANT 18 Aug 2021
Dr. Priyanka Popat Patil Dr Abhinandan Ravsaheb Patil Dr. Shivaji Pawar Dr. Sujit Kumar Mishra 2021105727
Figure 4 Schematic representation of the agar disc diffusion antibacterial activity
Signatory:
Dr. Priyanka Popat Patil
Dr Abhinandan Ravsaheb Patil
Dr. Shivaji Pawar
Dr. Sujit Kumar Mishra
Sheet 5 of 6
APPLICANT 18 Aug 2021
Dr. Priyanka Popat Patil Dr Abhinandan Ravsaheb Patil Dr. Shivaji Pawar Dr. Sujit Kumar Mishra 2021105727
Figure 5 Schematic representation of the agar well diffusion method for antibacterial activity.
Signatory:
Dr. Priyanka Popat Patil
Dr Abhinandan Ravsaheb Patil
Dr. Shivaji Pawar
Dr. Sujit Kumar Mishra
Sheet 6 of 6
APPLICANT 18 Aug 2021
Dr. Priyanka Popat Patil Dr Abhinandan Ravsaheb Patil Dr. Shivaji Pawar Dr. Sujit Kumar Mishra 2021105727
Figure 6 Schematic representation of shake flask method for antibacterial activity.
Signatory:
Dr. Priyanka Popat Patil
Dr Abhinandan Ravsaheb Patil
Dr. Shivaji Pawar
Dr. Sujit Kumar Mishra
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021105727A AU2021105727A4 (en) | 2021-08-18 | 2021-08-18 | A method of preparation of Silk Fibroins coated with Hybrid chitosan-ZnO nanoparticles for wound dressing. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021105727A AU2021105727A4 (en) | 2021-08-18 | 2021-08-18 | A method of preparation of Silk Fibroins coated with Hybrid chitosan-ZnO nanoparticles for wound dressing. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021105727A4 true AU2021105727A4 (en) | 2021-12-02 |
Family
ID=78716489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021105727A Ceased AU2021105727A4 (en) | 2021-08-18 | 2021-08-18 | A method of preparation of Silk Fibroins coated with Hybrid chitosan-ZnO nanoparticles for wound dressing. |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2021105727A4 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114271291A (en) * | 2021-12-31 | 2022-04-05 | 广东粤港澳大湾区国家纳米科技创新研究院 | Carboxymethyl chitosan coated nano zinc oxide material, preparation method and application thereof, plastic master batch and application thereof |
| CN114848890A (en) * | 2022-03-11 | 2022-08-05 | 安徽农业大学 | Antibacterial dressing capable of being dissolved as required and preparation method thereof |
-
2021
- 2021-08-18 AU AU2021105727A patent/AU2021105727A4/en not_active Ceased
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114271291A (en) * | 2021-12-31 | 2022-04-05 | 广东粤港澳大湾区国家纳米科技创新研究院 | Carboxymethyl chitosan coated nano zinc oxide material, preparation method and application thereof, plastic master batch and application thereof |
| CN114848890A (en) * | 2022-03-11 | 2022-08-05 | 安徽农业大学 | Antibacterial dressing capable of being dissolved as required and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9610378B2 (en) | Antimicrobial wound-covering material and method for manufacturing same | |
| RU2468129C2 (en) | Biopolymeric fibre, composition of forming solution for its obtaining, method of forming solution preparation, linen of biomedical purpose, biological bandage and method of wound treatment | |
| WO2019091150A1 (en) | Alginate wound repair dressing and preparation method thereof | |
| AU2021105727A4 (en) | A method of preparation of Silk Fibroins coated with Hybrid chitosan-ZnO nanoparticles for wound dressing. | |
| He et al. | Bacterial cellulose: functional modification and wound healing applications | |
| Shyna et al. | A nonadherent chitosan-polyvinyl alcohol absorbent wound dressing prepared via controlled freeze-dry technology | |
| RU2422133C1 (en) | Hydrophylic gel, method of its obtaining (versions), wound covering and based on it bandage means | |
| Liu et al. | Template-assisted magnetron sputtering of cotton nonwovens for wound healing application | |
| Salehi et al. | Kaolin-loaded chitosan/polyvinyl alcohol electrospun scaffold as a wound dressing material: In vitro and in vivo studies | |
| Bielecki et al. | Wound dressings and cosmetic materials from bacterial nanocellulose | |
| Liu et al. | Research progress on the use of micro/nano carbon materials for antibacterial dressings | |
| RU2683273C2 (en) | Chitin derivative active polymer layer, in particular, for dressing and application thereof | |
| CN114288464A (en) | Antibacterial healing-promoting hydrogel dressing and preparation method and application thereof | |
| CN109966540B (en) | Preparation method and application of nano chitin composite calcium alginate medical dressing | |
| Bülbül et al. | Traditional and advanced wound dressings: physical characterization and desirable properties for wound healing | |
| CN109432483B (en) | Medical dressing for accelerating wound healing and preparation method and application thereof | |
| Gupta et al. | Aloe vera loaded poly (vinyl alcohol)–poly (ethylene oxide)-carboxymethyl cellulose-polyester nonwoven membranes | |
| CN115850733A (en) | Injectable nano clay hydrogel and preparation method and application thereof | |
| Patil et al. | Wound dressing applications of nano-biofilms | |
| RU100724U1 (en) | ATRAUMATIC BANDING AGENT WITH NANOPARTICLES OF ASEPTICA SILVER | |
| Sun et al. | A nanofiber hydrogel derived entirely from ocean biomass for wound healing | |
| RU2270646C2 (en) | Dressing material | |
| TWI782850B (en) | Three-dimensional network aqueous gel and method for producing the same | |
| TWI804024B (en) | Production method of high oxygen-containing aqueous gel and high-oxygen aqueous gel | |
| RU114417U1 (en) | Dressing and multi-layer wound dressing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGI | Letters patent sealed or granted (innovation patent) | ||
| MK22 | Patent ceased section 143a(d), or expired - non payment of renewal fee or expiry |